

Efficacy and Safety of 144 Weeks of Bulevirtide 2 mg or 10 mg Monotherapy From the Ongoing Phase 3 Study MYR301

Pietro Lampertico^{1,2}, Soo Aleman³, Maurizia Brunetto^{4,5}, Antje Blank⁶, Pietro Andreone⁷, Pavel Bogomolov⁸, Vladimir Chulanov⁹, Nina Mamonova¹⁰, Natalia Geyvandova¹¹, Viacheslav Morozov¹², Olga Sagalova¹³, Tatyana Stepanova¹⁴, Grace M. Chee¹⁵, Dmitry Manuilov¹⁵, Mingyang Li¹⁵, Steve Tseng¹⁵, Audrey H. Lau¹⁵, Anu Osinus¹⁵, Julian Schulze zur Wiesch¹⁶, Markus Comberg¹⁷, Stefan Zeuzem¹⁸, Heiner Wedemeyer¹⁷

¹Division of Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ²Department of Pathophysiology and Transplantation, CRC "A. M. and A. Migliavacca" Centre for Liver Disease, University of Milan, Milan, Italy; ³Department of Infectious Diseases, Karolinska University Hospital/Karolinska Institutet, Stockholm, Sweden; ⁴Hepatology Unit, Reference Centre of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa, Pisa, Italy; ⁵Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; ⁶Medical Faculty Heidelberg/Heidelberg University Hospital, Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany; ⁷Internal Medicine, Baggiolaro Hospital, University of Modena and Reggio Emilia, Modena, Italy; ⁸M.F. Vladimirovsky Moscow Regional Research and Clinical Institute, Moscow, Russian Federation; ⁹Sechenov University, Moscow, Russian Federation; ¹⁰FSBI National Research Medical Centre for Phthisiopulmonology and Infectious Diseases of the Ministry of Health of the Russian Federation, Moscow, Russian Federation; ¹¹Stavropol Regional Hospital, Stavropol, Russian Federation; ¹²LLC Medical Company "Hepatolog," Samara, Russian Federation; ¹³South Ural State Medical University, Chelyabinsk, Russian Federation; ¹⁴LLC Clinic of Modern Medicine, Moscow, Russian Federation; ¹⁵Gilead Sciences, Inc., Foster City, CA, USA; ¹⁶Hepatology Outpatient Medical Clinic, University Hospital Hamburg-Eppendorf, Hamburg, Germany; ¹⁷Clinic for Gastroenterology, Hepatology, Infectious Diseases, and Endocrinology, Hannover Medical School, Hannover, Germany; ¹⁸Department of Medicine, University Hospital Frankfurt, Frankfurt, Germany

Conclusions

- Long-term treatment with BLV monotherapy over 144 weeks remained safe and effective
- Improvements in virologic and biochemical responses and liver stiffness, as well as low occurrence of liver-related outcomes, are supportive of the potential clinical benefits of long-term BLV monotherapy

Plain Language Summary

- Patients with chronic hepatitis delta who received bulevirtide for 144 weeks achieved substantial reductions in their hepatitis delta virus RNA levels and had either improved or maintained key markers of liver health and function

Introduction


- Hepatitis delta virus (HDV) infection affects between 10 and 20 million people worldwide¹ and causes the most severe form of chronic viral hepatitis^{2,3}
- Bulevirtide (BLV) is a first-in-class entry inhibitor approved in the EU, Great Britain, Switzerland, Australia, and the Russian Federation for treatment of chronic hepatitis delta (CHD)⁴⁻⁶ and is recommended by the European Association for the Study of the Liver (EASL) guidelines for the treatment of CHD in patients with compensated liver disease⁵
- Previously published results demonstrated that BLV 2 mg or 10 mg monotherapy for 96 weeks leads to HDV RNA reductions and alanine aminotransferase (ALT) improvements and is generally safe⁷

Objective

- The objective of this interim analysis was to evaluate the long-term efficacy and safety of BLV 2 mg or 10 mg monotherapy through 144 weeks of therapy

Methods

Figure 1 MYR301 Study Design



- The multicentre, open-label, randomised, Phase 3 study MYR301 (NCT03852719) was conducted at 16 sites across 4 countries (Germany, Italy, Russian Federation, and Sweden)
- Primary endpoint: the proportion of patients achieving a combined response (undetectable HDV RNA or $\geq 2 \log_{10}$ IU/mL decline from baseline [BL] and ALT normalisation) at week (W) 48
 - HDV RNA was manually extracted and viral load was quantified using RoboGene 2.0 (lower limit of quantification, 50 IU/mL)
- Endpoints evaluated over 144 weeks: the proportion of patients achieving key efficacy endpoints (virologic and biochemical), change in liver stiffness, liver related outcomes, changes in liver chemistries, and adverse events (AEs)
- Univariate logistic regression was conducted to evaluate if BL characteristics predicted undetectable HDV RNA at W144 for patients in arms B and C who completed W144 and had BL HDV RNA ≥ 250 IU/mL; predictors with P-value $< .05$ were considered significant

Results


Table 1 Baseline Demographics and Disease Characteristics

	BLV 2 mg (n = 49)	BLV 10 mg (n = 50)	Delayed Treatment to BLV 10 mg (n = 51)
Age, years, mean (SD)	44 (9)	41 (9)	41 (8)
Male sex, n (%)	30 (61)	30 (60)	26 (51)
Race, ^a n (%)			
White	41 (84)	43 (86)	40 (78)
Asian	8 (16)	6 (12)	11 (22)
Cirrhosis present, n (%)	23 (47)	24 (48)	24 (47)
Liver stiffness, kPa, mean (SD)	14.0 (8.2)	14.8 (9.3)	15.3 (9.0)
ALT, U/L, mean (SD)	108 (63)	123 (81)	102 (62)
HDV RNA, log ₁₀ IU/mL, mean (SD)	5.10 (1.20)	4.96 (1.46)	5.08 (1.36)
Genotype HDV-1, ^b n (%)	49 (100)	48 (96)	51 (100)
HBsAg, log ₁₀ IU/mL, mean (SD)	3.67 (0.52)	3.61 (0.59)	3.68 (0.47)
HBV DNA log ₁₀ IU/mL, mean (SD)	1.30 (1.29)	1.08 (1.26)	0.89 (0.99)
HBV genotype, n (%)			
A	2 (4)	2 (4)	2 (4)
D	47 (96)	44 (88)	44 (86)
Other/missing	0	4 (8)	5 (10)
Previous IFN therapy, n (%)	26 (53)	29 (58)	29 (57)
Concomitant HBV NA treatment, ^c n (%)	32 (65)	27 (54)	32 (63)

^aBLV 10 mg arm: Black, n = 1; ^bBLV 10 mg arm: HDV GT 5, n = 1; missing HDV GT, n = 1; ^cBLV 10 mg arm: HBV GT E, n = 1; delayed treatment to BLV 10 mg arm: unclassified HBV GT, n = 2. ^dAll patients who started NA therapy at or post BL, except 1, started at BL or within 2 days of BL. ALT, alanine aminotransferase; BL, baseline; BLV, bulevirtide; GT, genotype; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HDV, hepatitis delta virus; IFN, interferon; NA, nucleos(t)ide analogue; W, week.

- Patient retention remained high through 144 weeks with no discontinuations related to study treatment; study completion rates are below:
 - Arm A: 96% (49/51); pregnancy, 1; death (plasma cell myeloma unrelated to BLV), 1
 - Arm B: 92% (45/49); withdrew consent, 3; pregnancy, 1
 - Arm C: 88% (44/50); withdrew consent, 5; physician decision, 1


Figure 2 Key Efficacy Over Time, by BLV Duration



- Combined response, ALT normalisation, and virologic response rates increased through W96 and were maintained from W96 to W144; the response rates were similar between the BLV 2 mg and 10 mg arms
- Rates of undetectable HDV RNA continually increased over 144 weeks for both the BLV 2 mg and 10 mg arms; rates were numerically higher for the BLV 10 mg arm
- Among patients who achieved undetectable HDV RNA at any post-BL time points, those in the BLV 10 mg arm did so faster than in the BLV 2 mg arm
 - The mean (SD) numbers of weeks after starting BLV treatment to first reaching undetectable HDV RNA were
 - BLV 2 mg: 77 (45)
 - BLV 10 mg: 69 (41)

Results

Figure 3 Baseline Predictors of Undetectable HDV RNA at W144



- Lower HDV RNA and hepatitis B surface antigen (HBsAg) levels at BL were identified as potential predictors of undetectable HDV RNA at W144

Table 2 Platelet Count, Liver Chemistries, and Other Efficacy Markers Over Time

	BLV 2 mg (n = 49)			BLV 10 mg (n = 50)		
	BL	Week 96	Week 144	BL	Week 96	Week 144
Platelets, $\times 10^9/L$, mean (SD)	153 (52.5)	169 (69.1)	162 (62.5)	160 (53.1)	174 (70.7)	163 (63.5)
Platelets $< 90 \times 10^9/L$, %	14	13	14	12	11	14
Total bilirubin, $\mu\text{mol/L}$, median (Q1, Q3)	10.4 (6.7, 14.7)	12.7 (7.5, 15.9)	13.6 (8.6, 19.0)	10.5 (7.6, 13.6)	10.2 (7.5, 14.5)	11.8 (7.2, 15.0)
Albumin, g/L, mean (SD)	44 (3.1)	45 (2.6)	47 (2.9)	44 (3.2)	45 (3.2)	46 (3.3)
Albumin < 35 g/L, %	0	0	0	2	2	0
GGT, U/L, median (Q1, Q3)	57 (27, 73)	27 (18, 37)	25 (18, 37)	42 (27, 73)	24 (17, 36)	23 (19, 39)
INR, mean (SD)	1.12 (0.111)	1.10 (0.116)	1.12 (0.145)	1.14 (0.112)	1.10 (0.129)	1.14 (0.222)
HBsAg, log ₁₀ IU/mL, mean (SD)	3.67 (0.515)	3.47 (0.578)	3.29 (0.866)	3.61 (0.593)	3.47 (0.638)	3.41 (0.583)
Liver Stiffness, kPa, mean (SD)	13.99 (8.190)	10.2 (6.434)	9.43 (5.281)	14.81 (9.265)	10.04 (6.754)	11.28 (9.836)
Liver stiffness > 15 kPa, %	31	15	11	30	15	19

Values are based on available data. BL, baseline; BLV, bulevirtide; GGT, gamma-glutamyl transferase; HBsAg, hepatitis B surface antigen; INR, international normalised ratio; LS, least square; n/a, not applicable; Q, quartile.

- Platelet counts, liver chemistries, liver stiffness, and HBsAg values remained stable or improved over 144 weeks of BLV monotherapy, including for the subgroup with cirrhosis (data not shown)

Liver-Related Outcomes and Other Endpoints

- No patients had progression to liver-related outcomes over 144 weeks, except for 1 case of mild ascites (arm A) that occurred 165 days after switching to BLV 10 mg in a patient with cirrhosis at BL; the ascites resolved while on BLV
- Only 1 patient experienced HBsAg loss in the delayed treatment to BLV 10 mg arm, and no participant experienced HBsAg seroconversion

Table 3 Overall Safety Summary

	BLV 2 mg (n = 49)		BLV 10 mg (n = 50)		Delayed Treatment to BLV 10 mg (n = 51)	
	Week 96	Week 144	Week 96	Week 144	Week 48–Week 96 ^a	Week 48–Week 144
Patients, n (%)	47 (96)	48 (98)	48 (96)	48 (96)	48 (84)	46 (92)
Any AE	9 (18)	12 (24)	8 (16)	10 (20)	3 (6)	5 (10)
Any grade 3–4 AE	2 (4)	3 (6)	4 (8)	6 (12)	2 (4)	3 (6)
Any SAE	0	0	0	0	0	0
Any SAE related to BLV	0	0	0	0	0	0
Any AE leading to withdrawal of BLV	0	0	0	0	0	0
Any AE related to BLV	25 (51)	27 (55)	36 (72)	37 (74)	22 (44)	23 (46)
Death	0	0	0	0	1 (2) ^b	1 (2) ^b
Laboratory abnormalities, total bile salts ($\mu\text{mol/L}$), mean (SD)	24 (26)	28 (40)	52 (83)	59 (63)	63 (50) ^c	64 (59) ^c
AEs of interest ^d						
Headache	9 (18)	10 (20)	12 (24)	12 (24)	7 (14)	7 (14)
Dizziness	2 (4)	2 (4)	4 (8)	4 (8)	1 (2)	1 (2)
Nausea	3 (6)	3 (6)	6 (12)	6 (12)	1 (2)	1 (2)
Pruritus	6 (12)	6 (12)	9 (18)	8 (16)	0	0
Fatigue	7 (14)	7 (14)	9 (18)	9 (18)	2 (4)	3 (6)
ISR ^e	10 (20)	10 (20)	15 (30)	15 (30)	6 (12)	8 (16)

All AEs were treatment emergent. AEs from the first 96 weeks are from Wedemeyer H, et al. (2024)⁷. AEs from the first 48 weeks are not shown. ^aOne death due to plasma cell myeloma not related to study treatment. ^bFor the delayed treatment to 10 mg arm, week 96 and 144 total bile salt values reflect weeks 48 and 96 of BLV 10 mg treatment, respectively. ^cAEs of interest that occurred at higher frequencies in BLV treatment groups compared with the delayed treatment group. ^dGrouped term including injection-site AEs (bruising, induration, reaction, erythema, pruritus, swelling, pain, haematoma, rash, dermatitis). AE, adverse event; BLV, bulevirtide; ISR, injection-site reaction; SAE, serious adverse event.

- There were no drug discontinuations, serious AEs, or deaths attributed to BLV monotherapy and no reports of HBV reactivation (regardless of concomitant nucleos(t)ide analogue therapy) through 144 weeks of treatment
- The safety profile was similar between the BLV 2 mg and 10 mg arms, except for injection-site reactions, which were more frequent in the BLV 10 mg arm (likely due to 2 daily BLV injections vs 1 daily injection with BLV 2 mg)
- Dose-dependent elevations in bile acid salts remained asymptomatic and were not associated with any clinical sequelae throughout 144 weeks of treatment